Efficacy and safety of sitafloxacin (STFX) for low-risk febrile neutropenia in patients with lung cancer, phase II study,
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
Price : $35 *
At a glance
- Drugs Sitafloxacin (Primary)
- Indications Bacterial infections; Febrile neutropenia
- Focus Therapeutic Use
- 29 Mar 2018 Status changed from recruiting to completed.
- 27 Jun 2013 New trial record
- 17 Jun 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.